Systemic inflammation in nonalcoholic fatty liver disea levels of CCL2

Journal of Hepatology

44, 1167-1174

DOI: 10.1016/j.jhep.2006.02.011

Citation Report

#	Article	IF	Citations
1	Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease. Journal of Hepatology, 2006, 45, 879-881.	3.7	79
2	Inflammatory interactions between nonalcoholic fatty liver disease and the metabolic syndrome. Journal of Hepatology, 2006, 45, 881-882.	3.7	21
3	Hepatocyte Growth Factor Induces Glucose Uptake in 3T3-L1 Adipocytes through A Gab1/Phosphatidylinositol 3-Kinase/Glut4 Pathway. Journal of Biological Chemistry, 2007, 282, 10325-10332.	3.4	36
4	The Role of Cytokines and Chemokines in the Development of Steatohepatitis. Seminars in Liver Disease, 2007, 27, 173-193.	3.6	106
5	Correlation of Serum TNF-Î± Levels and Histologic Liver Injury Scores in Pediatric Nonalcoholic Fatty Liver Disease. American Journal of Clinical Pathology, 2007, 127, 954-960.	0.7	162
6	Genes Involved in Fatty Acid Partitioning and Binding, Lipolysis, Monocyte/Macrophage Recruitment, and Inflammation Are Overexpressed in the Human Fatty Liver of Insulin-Resistant Subjects. Diabetes, 2007, 56, 2759-2765.	0.6	306
7	Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. American Journal of Clinical Nutrition, 2007, 86, 285-300.	4.7	352
8	Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis, 2007, 191, 235-240.	0.8	500
9	Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to highâ€fat diet. Hepatology Research, 2007, 37, 50-57.	3.4	196
10	Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease. Expert Review of Molecular Diagnostics, 2007, 7, 195-205.	3.1	14
11	Prostacyclin in liver disease: a potential therapeutic option. Expert Opinion on Biological Therapy, 2007, 7, 785-790.	3.1	7
12	Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Present and future. Hepatology, 2007, 46, 582-589.	7.3	393
13	Serum cytokines as biomarkers of disease and clues to pathogenesis. Hepatology, 2007, 46, 6-8.	7.3	24
14	Inflammation: a way to understanding the evolution of portal hypertension. Theoretical Biology and Medical Modelling, 2007, 4, 44.	2.1	57
15	High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. Journal of Gastroenterology, 2007, 42, 573-582.	5.1	247
16	Nonalcoholic fatty liver disease and cardiovascular disease risk. Current Diabetes Reports, 2007, 7, 181-187.	4.2	29
17	A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatology International, 2008, 2, 196-201.	4.2	64
18	Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells. Journal of Gastroenterology, 2008, 43, 298-304.	5.1	93

#	Article	IF	Citations
19	Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. Hepatology, 2008, 48, 670-678.	7.3	176
20	NASH Predicts Plasma Inflammatory Biomarkers Independently of Visceral Fat in Men. Obesity, 2008, 16, 1394-1399.	3.0	180
21	Clinical trial: insulinâ€sensitizing agents may reduce consequences of insulin resistance in individuals with nonâ€alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2008, 28, 200-208.	3.7	108
22	Rubratoxin B induces interleukin-6 secretion in mouse white adipose tissues and 3T3-L1 adipocytes. Toxicology Letters, 2008, 182, 79-83.	0.8	3
23	Cytokines in the Pathogenesis of Fatty Liver and Disease Progression to Steatohepatitis: Implications for Treatment. American Journal of Gastroenterology, 2008, 103, 1036-1042.	0.4	178
24	Chronic prehepatic portal hypertension in the rat: is it a type of Metabolic Inflammatory Syndrome?. Lipids in Health and Disease, 2008, 7, 4.	3.0	18
25	Clinical and pathologic risk factors for atherosclerosis in cirrhosis: A comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies. Journal of Hepatology, 2008, 49, 595-599.	3.7	102
26	Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends in Molecular Medicine, 2008, 14, 72-81.	6.7	381
27	Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends in Endocrinology and Metabolism, 2008, 19, 371-379.	7.1	402
28	Fatty Liver. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 27-38.	2.4	717
29	Increased Hepatic and Circulating Interleukin-6 Levels in Human Nonalcoholic Steatohepatitis. American Journal of Gastroenterology, 2008, 103, 1372-1379.	0.4	531
30	Antioxidant supplemention in the treatment of skeletal muscle insulin resistance: potential mechanisms and clinical relevance. Applied Physiology, Nutrition and Metabolism, 2008, 33, 21-31.	1.9	20
31	In Search of an Ideal Biomarker for Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2008, 103, 1380-1382.	0.4	2
32	Association Between Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease: A First Message Should Pass. American Journal of Gastroenterology, 2008, 103, 3036-3038.	0.4	24
33	Homocysteine Induces Monocyte Chemoattractant Protein-1 Expression in Hepatocytes Mediated via Activator Protein-1 Activation. Journal of Biological Chemistry, 2008, 283, 1282-1292.	3.4	31
34	Gene expression in human NAFLD. American Journal of Physiology - Renal Physiology, 2008, 294, G1281-G1287.	3.4	356
35	Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy. American Journal of Physiology - Endocrinology and Metabolism, 2008, 295, E85-E91.	3.5	56
36	Diagnosis of Nonalcoholic Fatty Liver Disease: Invasive versus Noninvasive. Seminars in Liver Disease, 2008, 28, 386-395.	3.6	257

#	Article	IF	Citations
37	Dietary single cell protein reduces fatty liver in obese Zucker rats. British Journal of Nutrition, 2008, 100, 776-785.	2.3	11
38	Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. Clinical Science, 2008, 115, 1-12.	4.3	60
39	Molecular Basis of Liver Disease. , 2009, , 395-419.		0
40	IL-6 Deficiency Attenuates Murine Diet-Induced Non-Alcoholic Steatohepatitis. PLoS ONE, 2009, 4, e7929.	2.5	75
41	Noninvasive diagnosis of nonalcoholic fatty liver disease. Annals of Hepatology, 2009, 8, S25-S33.	1.5	40
42	A Complex Role of Activin A in Non-Alcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2009, 104, 2196-2205.	0.4	62
43	Relationship of serum bilirubin concentrations to kidney function and albuminuria in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001â€“2006. Clinical Chemistry and Laboratory Medicine, 2009, 47, 1055-62.	2.3	43
44	IDENTIFYING NON-ALCOHOLIC FATTY LIVER DISEASE AMONG ASYMPTOMATIC OVERWEIGHT AND OBESE INDIVIDUALS BY CLINICAL AND BIOCHEMICAL CHARACTERISTICS. Acta Clinica Belgica, 2009, 64, 483-493.	1.2	31
45	Nonalcoholic Fatty Liver Disease as a Contributor to Hypercoagulation and Thrombophilia in the Metabolic Syndrome. Seminars in Thrombosis and Hemostasis, 2009, 35, 277-287.	2.7	123
46	Adipokines in Nonalcoholic Steatohepatitis: From Pathogenesis to Implications in Diagnosis and Therapy. Mediators of Inflammation, 2009, 2009, 1-8.	3.0	105
47	Arsenic and Cardiovascular Disease. Toxicological Sciences, 2009, 107, 312-323.	3.1	280
48	A casein diet added isoflavone-enriched soy protein favorably affects biomarkers of steatohepatitis in obese Zucker rats. Nutrition, 2009, 25, 574-580.	2.4	32
49	Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology, 2009, 49, 306-317.	7.3	491
50	Serum Level of Adiponectin Correlated with Gender and Genotype in Patients with Chronic Hepatitis C. Digestive Diseases and Sciences, 2009, 54, 1120-1127.	2.3	5
51	Inhibition of the chemokine (Câ€“C motif) ligand 2/chemokine (Câ€“C motif) receptor 2 pathway attenuates hyperglycaemia and inflammation in a mouse model of hepatic steatosis and lipoatrophy. Diabetologia, 2009, 52, 972-981.	6.3	57
52	Serum procalcitonin and CRP levels in non-alcoholic fatty liver disease: a case control study. BMC Gastroenterology, 2009, 9, 16.	2.0	51
53	Association of monocyte chemoattractant proteinâ€1 with adipocyte number, insulin resistance and liver function markers. Journal of Medical Primatology, 2009, 38, 418-424.	0.6	12
54	Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liver International, 2009, 29, 988-996.	3.9	74

#	Article	IF	Citations
55	Hepatic monocyte chemoattractant protein-1 is upregulated by dietary cholesterol and contributes to liver steatosis. Cytokine, 2009, 48, 273-279.	3.2	48
57	Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. Journal of Hepatology, 2009, 50, 1102-1111.	3.7	186
58	Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. Journal of Hepatology, 2009, 51, 380-388.	3.7	259
59	Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. Journal of Hepatology, 2009, 51, 758-764.	3.7	217
60	Non-alcoholic fatty liver disease pathogenesis: The present and the future. Digestive and Liver Disease, 2009, 41, 615-625.	0.9	222
61	Predictors of Steatohepatitis and Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease. Clinics in Liver Disease, 2009, 13, 591-606.	2.1	27
62	Protective effects of SP600125 in a diet-induced rat model of non-alcoholic steatohepatitis. Scandinavian Journal of Gastroenterology, 2009, 44, 1356-1362.	1.5	9
63	Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis, 2009, 204, 521-525.	0.8	123
64	Oxidative stress and human diseases: Origin, link, measurement, mechanisms, and biomarkers. Critical Reviews in Clinical Laboratory Sciences, 2009, 46, 241-281.	6.1	348
65	Protein array technology to investigate cytokine production by monocytes from patients with advanced alcoholic cirrhosis: An ex vivo pilot study. Hepatology Research, 2009, 39, 706-715.	3.4	15
66	Î±â€Glucosidase inhibitor acarbose and sequestome 1/A170/p62 deficient mice: A promising therapy and unique model for nonâ€alcoholic fatty liver disease. Hepatology Research, 2009, 39, 845-846.	3.4	1
67	Highly Purified Eicosapentaenoic Acid Ethyl Ester Prevents Development of Steatosis and Hepatic Fibrosis in Rats. Digestive Diseases and Sciences, 2010, 55, 631-641.	2.3	27
68	Nonalcoholic Fatty Liver Disease: A Review and Update. Digestive Diseases and Sciences, 2010, 55, 560-578.	2.3	287
69	Effect of maternal diet rich in omegaâ€6 and omegaâ€9 fatty acids on the liver of LDL receptorâ€deficient mouse offspring. Birth Defects Research Part B: Developmental and Reproductive Toxicology, 2010, 89, 164-170.	1.4	12
70	Xanthohumol, a chalcon derived from hops, inhibits hepatic inflammation and fibrosis. Molecular Nutrition and Food Research, 2010, 54, S205-13.	3.3	82
71	Psoriasis, the liver, and the gastrointestinal tract. Dermatologic Therapy, 2010, 23, 155-159.	1.7	35
72	Attenuated progression of diet-induced steatohepatitis in glutathione-deficient mice. Laboratory Investigation, 2010, 90, 1704-1717.	3.7	67
73	Monocyte chemoattractant protein-1 deficiency does not affect steatosis or inflammation in livers of mice fed a methionineâ€"choline-deficient diet. Laboratory Investigation, 2010, 90, 1794-1804.	3.7	37

#	Article	IF	Citations
75	The effect of obesity on intrahepatic cytokine and chemokine expression in chronic hepatitis C infection. Gut, 2010, 59, 397-404.	12.1	29
76	Intracellular Nicotinamide Phosphoribosyltransferase Protects against Hepatocyte Apoptosis and Is Down-Regulated in Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3039-3047.	3.6	89
77	Novel Insights into the Pathophysiology of Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 2010, 30, 391-401.	3.6	106
78	Nonalcoholic steatohepatitis: risk factors and diagnosis. Expert Review of Gastroenterology and Hepatology, 2010, 4, 623-635.	3.0	45
79	Pathogenesis of non-alcoholic fatty liver disease. QJM - Monthly Journal of the Association of Physicians, 2010, 103, 71-83.	0.5	581
80	Pro-coagulant imbalance in patients with chronic liver disease. Journal of Hepatology, 2010, 53, 586-587.	3.7	8
81	Non-alcoholic fatty liver disease, alcohol intake and psoriasis. Journal of Hepatology, 2010, 53, 587.	3.7	6
82	Tissue Factor-Deficiency and Protease Activated Receptor-1-Deficiency Reduce Inflammation Elicited by Diet-Induced Steatohepatitis in Mice. American Journal of Pathology, 2010, 176, 177-186.	3.8	40
83	Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. Atherosclerosis, 2010, 209, 585-591.	0.8	105
84	Bioinformatics Methods in Clinical Research. Methods in Molecular Biology, 2010, , .	0.9	15
85	Redox Balance in the Pathogenesis of Nonalcoholic Fatty Liver Disease: Mechanisms and Therapeutic Opportunities. Antioxidants and Redox Signaling, 2011, 15, 1325-1365.	5.4	128
86	Fatty liver disease in obese children â€“ relation to other metabolic risk factors. Pediatric Obesity, 2011, 6, 59-64.	3.2	20
87	The role of oxidative stress in non-alcoholic steatohepatitis. Clinica Chimica Acta, 2011, 412, 1297-1305.	1.1	268
88	C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. Journal of Hepatology, 2011, 55, 660-665.	3.7	98
89	Clinicopathological features of nonâ€alcoholic fatty liver disease. Hepatology Research, 2011, 41, 911-920.	3.4	25
90	Some inflammatory cytokine levels, iron metabolism and oxidan stress markers in subjects with nonalcoholic steatohepatitis. Clinical Biochemistry, 2011, 44, 1375-1379.	1.9	48
91	The Severity of Fatty Liver Disease Relating to Metabolic Abnormalities Independently Predicts Coronary Calcification. Radiology Research and Practice, 2011, 2011, 1-8.	1.3	12
92	Recent Insights into the Relationship between Inflammatory Liver Diseases and Atherosclerosis. Journal of Investigative Medicine, 2011, 59, 904-911.	1.6	15

#	Article	IF	Citations
93	Inflammatory stress exacerbates hepatic cholesterol accumulation via increasing cholesterol uptake and de novo synthesis. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 875-883.	2.8	78
94	Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. Liver International, 2011, 31, 176-183.	3.9	95
95	Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease. Liver International, 2011, 31, 461-473.	3.9	41
96	Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis. Journal of Digestive Diseases, 2011, 12, 10-16.	1.5	76
97	Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism: Clinical and Experimental, 2011, 60, 313-326.	3.4	272
98	Elevated systemic monocyte chemoattractrant protein-1 in hepatic steatosis without significant hepatic inflammation. Experimental and Molecular Pathology, 2011, 91, 780-783.	2.1	33
99	Fatty acids and the endoplasmic reticulum in nonalcoholic fatty liver disease. BioFactors, 2011, 37, 8-16.	5.4	115
100	Eicosapentaenoic Acid Attenuates Progression of Hepatic Fibrosis with Inhibition of Reactive Oxygen Species Production in Rats Fed Methionine- and Choline-Deficient Diet. Digestive Diseases and Sciences, 2011, 56, 1065-1074.	2.3	48
101	Correlation Analysis Between Gene Expression Profile of Rat Liver Tissues and High-Fat Emulsion-Induced Nonalcoholic Fatty Liver. Digestive Diseases and Sciences, 2011, 56, 2299-2308.	2.3	31
102	Telmisartan improves nonalcoholic steatohepatitis in medaka (Oryzias latipes) by reducing macrophage infiltration and fat accumulation. Cell and Tissue Research, 2011, 344, 125-134.	2.9	35
103	Activin A in Nonalcoholic Fatty Liver Disease. Vitamins and Hormones, 2011, 85, 323-342.	1.7	9
104	Relevance ofTNF-Î± gene polymorphisms in nonalcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2011, 5, 155-158.	3.0	6
105	Hepatic Steatosis, Obesity, and the Metabolic Syndrome Are Independently and Additively Associated With Increased Systemic Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1927-1932.	2.4	144
106	Participation of bile ductular cells in the pathological progression of non-alcoholic fatty liver disease. Journal of Clinical Pathology, 2011, 64, 564-570.	2.0	37
107	Fish oil improves lipid metabolism and ameliorates inflammation in patients with metabolic syndrome: Impact of nonalcoholic fatty liver disease. Pharmaceutical Biology, 2012, 50, 297-303.	2.9	23
108	Lack of CC chemokine ligand 2 differentially affects inflammation and fibrosis according to the genetic background in a murine model of steatohepatitis. Clinical Science, 2012, 123, 459-471.	4.3	59
109	Kuppfer Cells Trigger Nonalcoholic Steatohepatitis Development in Diet-induced Mouse Model through Tumor Necrosis Factor-Î± Production. Journal of Biological Chemistry, 2012, 287, 40161-40172.	3.4	343
110	Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. European Journal of Endocrinology, 2012, 166, 503-510.	3.7	150

#	Article	IF	Citations
111	N-Acetylglucosaminyltransferase V regulates TGF-Î² response in hepatic stellate cells and the progression of steatohepatitis. Glycobiology, 2012, 22, 778-787.	2.5	26
112	Effects and Mechanism of Turmeric Vasorelaxation of the Thoracic Aorta in Hypercholesterolemic Rats. Journal of Medicinal Food, 2012, 15, 190-199.	1.5	10
113	Metabolic syndrome in psoriasis. Advances in Dermatology and Allergology, 2012, 5, 356-362.	1.0	2
114	Association between the Severity of Nonalcoholic Fatty Liver Disease and High Sensitivity C-reactive Protein in Adults. The Korean Journal of Obesity, 2012, 21, 166.	0.2	1
115	Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease. Experimental Diabetes Research, 2012, 2012, 1-12.	3.8	182
116	Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options. Current Vascular Pharmacology, 2012, 10, 162-172.	1.7	42
117	Analysis of adipokine concentrations in paediatric nonâ€alcoholic fatty liver disease. Pediatric Obesity, 2012, 7, 471-479.	2.8	42
118	NASH and atherosclerosis are two aspects of a shared disease: Central role for macrophages. Atherosclerosis, 2012, 220, 287-293.	0.8	79
119	Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut, 2012, 61, 416-426.	12.1	485
120	Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. Journal of Hepatology, 2012, 56, 1363-1370.	3.7	198
121	Therapeutic Administration of the Direct Thrombin Inhibitor Argatroban Reduces Hepatic Inflammation in Mice with Established Fatty Liver Disease. American Journal of Pathology, 2012, 181, 1287-1295.	3.8	35
122	Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease. Journal of Clinical and Experimental Hepatology, 2012, 2, 145-155.	0.9	36
123	Association between Serum Interleukin-6 Concentrations and Mortality in Older Adults: The Rancho Bernardo Study. PLoS ONE, 2012, 7, e34218.	2.5	58
124	Cholesterol and Inflammation at the Crossroads of Non-Alcoholic Fatty Liver Disease (NAFLD) and Atherogenesis. , 0, , .		2
125	Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2012, 18, 3945.	3.3	64
126	NASH is an Infl ammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut and Liver, 2012, 6, 149-171.	2.9	334
127	Non-Alcoholic Fatty Liver Disease, a Marker of Subclinical Atherosclerosis Applicable Only to Metabolic Syndrome?: Time to Organize the Connection between Metabolism and Atherosclerosis. Journal of Cardiovascular Imaging, 2012, 20, 124.	0.8	4
128	Role of cytokines and chemokines in non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2012, 18, 727.	3.3	280

#	Article	IF	Citations
129	Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology, 2012, 55, 1369-1378.	7.3	67
130	Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radical Biology and Medicine, 2012, 52, 59-69.	2.9	743
131	Direct Peritoneal Resuscitation Improves Obesity-Induced Hepatic Dysfunction after Trauma. Journal of the American College of Surgeons, 2012, 214, 517-528.	0.5	10
132	Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes. European Journal of Pharmacology, 2012, 685, 156-164.	3.5	33
133	Inflammatory stress exacerbates hepatic cholesterol accumulation via disrupting cellular cholesterol export. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 974-984.	2.8	41
134	The effects of detraining on blood adipokines and antioxidant enzyme in Korean overweight children. European Journal of Pediatrics, 2012, 171, 235-243.	2.7	23
135	The role of angiotensin II in nonalcoholic steatohepatitis. Molecular and Cellular Endocrinology, 2013, 378, 29-40.	3.2	57
136	Alterations in the redox state and liver damage: Hints from the EASL Basic School of Hepatology. Journal of Hepatology, 2013, 58, 365-374.	3.7	51
137	Genetics of Nonalcoholic Fatty Liver Disease: An Overview. Journal of Genetics and Genomics, 2013, 40, 15-22.	3.9	23
138	Inhibition of Glutaminyl Cyclases alleviates <scp>CCL</scp>2â€mediated inflammation of nonâ€alcoholic fatty liver disease in mice. International Journal of Experimental Pathology, 2013, 94, 217-225.	1.3	26
139	Structural changes of gut microbiota in a rat non-alcoholic fatty liver disease model treated with a Chinese herbal formula. Systematic and Applied Microbiology, 2013, 36, 188-196.	2.8	83
140	The pro-inflammatory action of tumour necrosis factor-Î± in non-alcoholic steatohepatitis is independent of the NSMAF gene product. Digestive and Liver Disease, 2013, 45, 147-154.	0.9	6
141	Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine, 2013, 43, 100-107.	2.3	72
142	Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. Journal of Hepatology, 2013, 58, 1007-1019.	3.7	332
143	Brahma-related gene 1 bridges epigenetic regulation of proinflammatory cytokine production to steatohepatitis in mice. Hepatology, 2013, 58, 576-588.	7.3	93
144	Amelioration of hepatic inflammation in a mouse model of NASH using a dithiocarbamate derivative. Hepatology International, 2013, 7, 600-609.	4.2	9
145	The relationship between oxidative stress and nonalcoholic fatty liver disease: Its effects on the development of nonalcoholic steatohepatitis. Redox Report, 2013, 18, 127-133.	4.5	113
146	Diagnosis and Management of Nonalcoholic Fatty Liver Disease and Its Hemostatic/Thrombotic and Vascular Complications. Seminars in Thrombosis and Hemostasis, 2013, 39, 214-228.	2.7	56

#	Article	IF	Citations
147	CholineÊ¼s role in maintaining liver function. Current Opinion in Clinical Nutrition and Metabolic Care, 2013, 16, 339-345.	2.5	92
148	Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Journal of Clinical Pathology, 2013, 66, 1033-1045.	2.0	70
149	Pathophysiology of NASH: Perspectives for a Targeted Treatment. Current Pharmaceutical Design, 2013, 19, 5250-5269.	1.9	140
150	Knowledge-Based Identification of Soluble Biomarkers: Hepatic Fibrosis in NAFLD as an Example. PLoS ONE, 2013, 8, e56009.	2.5	15
151	CCR2 and CD44 Promote Inflammatory Cell Recruitment during Fatty Liver Formation in a Lithogenic Diet Fed Mouse Model. PLoS ONE, 2013, 8, e65247.	2.5	26
152	Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD. Current Pharmaceutical Design, 2013, 19, 5177-5192.	1.9	100
153	Garcinia Cambogiaattenuates diet-induced adiposity but exacerbates hepatic collagen accumulation and inflammation. World Journal of Gastroenterology, 2013, 19, 4689.	3.3	75
154	Therapeutic Role of Ursolic Acid on Ameliorating Hepatic Steatosis and Improving Metabolic Disorders in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Rats. PLoS ONE, 2014, 9, e86724.	2.5	112
155	Prediction of Metabolic Syndrome by Non-Alcoholic Fatty Liver Disease in Northern Urban Han Chinese Population: A Prospective Cohort Study. PLoS ONE, 2014, 9, e96651.	2.5	22
156	Molecular pathways in non-alcoholic fatty liver disease. Clinical and Experimental Gastroenterology, 2014, 7, 221.	2.3	279
157	Diagnosis of Non-alcoholic Fatty Liver Disease. Journal of Korean Diabetes, 2014, 15, 82.	0.3	0
158	The Levels of Soluble Intercellular Adhesion Molecule, Vascular Adhesion Molecule and Se-Selectin Levels in Patients with Non-Alcoholic Fatty Liver Disease. , 2014, 05, .		2
159	Aberrant Hepatic MicroRNA Expression in Nonalcoholic Fatty Liver Disease. Cellular Physiology and Biochemistry, 2014, 34, 1983-1997.	1.6	74
160	Serological and Histological Examination of a Nonalcoholic Steatohepatitis Mouse Model Created via the Administration of Monosodium Glutamate. International Scholarly Research Notices, 2014, 2014, 1-7.	0.9	6
161	Roles of Chronic Low-Grade Inflammation in the Development of Ectopic Fat Deposition. Mediators of Inflammation, 2014, 2014, 1-7.	3.0	51
162	Genistein alleviates the development of nonalcoholic steatohepatitis in <scp>A</scp>po<scp>E</scp>^{â€•/â€•} mice fed a highâ€fat diet. Molecular Nutrition and Food Research, 2014, 58, 830-841.	3.3	48
163	Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds. Molecular Nutrition and Food Research, 2014, 58, 147-171.	3.3	77
164	The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease. Hepatology, 2014, 59, 1393-1405.	7.3	344

#	Article	IF	Citations
165	Changes in the levels of endothelium-derived coagulation parameters in nonalcoholic fatty liver disease. Blood Coagulation and Fibrinolysis, 2014, 25, 151-155.	1.0	12
166	Evidence of endoplasmic reticulum stress and liver inflammation in the American mink Neovison vison with benign hepatic steatosis. Journal of Comparative Physiology B: Biochemical, Systemic, and Environmental Physiology, 2014, 184, 913-927.	1.5	2
167	Role of Innate Immune Response in Non-Alcoholic Fatty Liver Disease: Metabolic Complications and Therapeutic Tools. Frontiers in Immunology, 2014, 5, 177.	4.8	116
168	Pediatric Non-Alcoholic Fatty Liver Disease/Oboljenje Ne-Alkoholne Masne Jetre U Pedijatriji. Journal of Medical Biochemistry, 2014, 34, 3-12.	1.7	3
169	Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Postgraduate Medical Journal, 2014, 90, 254-266.	1.8	12
170	Serum cytokeratinâ€18 in the diagnosis of nonâ€alcoholic steatohepatitis: A metaâ€analysis. Hepatology Research, 2014, 44, 854-862.	3.4	36
171	Mitochondrial Dysfunction in Obesity-Associated Nonalcoholic Fatty Liver Disease: The Protective Effects of Pomegranate with Its Active Component Punicalagin. Antioxidants and Redox Signaling, 2014, 21, 1557-1570.	5.4	104
172	Effects of Callistephus chinensis flower polyphones on improving metabolic disorders in high-fat diet-induced mice. Food and Function, 2014, 5, 3304-3310.	4.6	2
173	Fatty liverâ€induced changes in stereotypic behavior in rats and effects of glucagonâ€like peptideâ€1 analog on stereotypy. Kaohsiung Journal of Medical Sciences, 2014, 30, 447-452.	1.9	4
174	Roles for Chemokines in Liver Disease. Gastroenterology, 2014, 147, 577-594.e1.	1.3	634
175	The molecular pathogenic role of inflammatory stress in dysregulation of lipid homeostasis and hepatic steatosis. Genes and Diseases, 2014, 1, 106-112.	3.4	33
176	Systematic review with metaâ€analysis: nonâ€invasive assessment of nonâ€alcoholic fatty liver disease â€“ the role of transient elastography and plasma cytokeratinâ€18 fragments. Alimentary Pharmacology and Therapeutics, 2014, 39, 254-269.	3.7	320
177	Lipids in health and disease. Nature, 2014, 510, 47-47.	27.8	24
178	Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine, 2014, 47, 70-80.	2.3	206
179	Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 18070.	3.3	260
180	Maternal Protein and Fat Intake: Epigenetic Consequences on Fetal Development. Oxidative Stress and Disease, 2014, , 87-110.	0.3	0
181	Research advances in the relationship between nonalcoholic fatty liver disease and atherosclerosis. Lipids in Health and Disease, 2015, 14, 158.	3.0	45
182	Serum autotaxin is independently associated with hepatic steatosis in women with severe obesity. Obesity, 2015, 23, 965-972.	3.0	33

#	Article	IF	Citations
183	Interferon gamma-induced protein 10 is associated with insulin resistance and incident diabetes in patients with nonalcoholic fatty liver disease. Scientific Reports, 2015, 5, 10096.	3.3	38
184	Association of periodontal status with liver abnormalities and metabolic syndrome. Journal of Oral Science, 2015, 57, 335-343.	1.7	24
185	Investigation into the antioxidant role of arginine in the treatment and the protection for intralipid-induced non-alcoholic steatohepatitis. Lipids in Health and Disease, 2015, 14, 128.	3.0	16
186	INFLUENCE OF OXIDATIVE STRESS AND OBESITY IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS. Arquivos De Gastroenterologia, 2015, 52, 228-233.	0.8	12
187	LPSF/GQ-02 Inhibits the Development of Hepatic Steatosis and Inflammation in a Mouse Model of Non-Alcoholic Fatty Liver Disease (NAFLD). PLoS ONE, 2015, 10, e0123787.	2.5	13
188	Understanding Nutritional Interventions and Physical Exercise in Non-Alcoholic Fatty Liver Disease. Current Molecular Medicine, 2015, 15, 3-26.	1.3	28
189	Intervening TNF-Î±via PPARÎ³with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-10.	1.2	13
190	Fatty liver and abdominal fat relationships with high C-reactive protein in adults without coronary heart disease. Annals of Hepatology, 2015, 14, 658-665.	1.5	3
191	Isolevuglandin-Type Lipid Aldehydes Induce the Inflammatory Response of Macrophages by Modifying Phosphatidylethanolamines and Activating the Receptor for Advanced Glycation Endproducts. Antioxidants and Redox Signaling, 2015, 22, 1633-1645.	5.4	25
192	Chronic inflammation aggravates metabolic disorders of hepatic fatty acids in high-fat diet-induced obese mice. Scientific Reports, 2015, 5, 10222.	3.3	45
193	Usefulness of Cytokeratin-18M65 in Diagnosing Non-Alcoholic Steatohepatitis in Japanese Population. Digestive Diseases, 2015, 33, 715-720.	1.9	9
194	Flaxseed oil containing flaxseed oil ester of plant sterol attenuates high-fat diet-induced hepatic steatosis in apolipoprotein-E knockout mice. Journal of Functional Foods, 2015, 13, 169-182.	3.4	12
195	Lipoapoptosis induced by saturated free fatty acids stimulates monocyte migration: a novel role for Pannexin1 in liver cells. Purinergic Signalling, 2015, 11, 347-359.	2.2	25
196	Physiology and pathophysiology of liver lipid metabolism. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1055-1067.	3.0	77
197	New Medical Treatment Strategies for Nonalcoholic Steatohepatitis. Current Treatment Options in Gastroenterology, 2015, 13, 259-273.	0.8	3
198	Hypocholesterolemic effects ofCurcuma longaL. withNelumbo nuciferaleaf in anin vitromodel and a high cholesterol diet-induced hypercholesterolemic mouse model. Animal Cells and Systems, 2015, 19, 133-143.	2.2	3
199	AMP-kinase pathway is involved in tumor necrosis factor alpha-induced lipid accumulation in human hepatoma cells. Life Sciences, 2015, 131, 23-29.	4.3	30
200	Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice. Life Sciences, 2015, 139, 132-138.	4.3	9

#	Article	IF	Citations
201	Oligonol suppresses lipid accumulation and improves insulin resistance in a palmitate-induced in HepG2 hepatocytes as a cellular steatosis model. BMC Complementary and Alternative Medicine, 2015, 15, 185.	3.7	45
202	Increased Serum Levels of LIGHT/TNFSF14 in Nonalcoholic Fatty Liver Disease: Possible Role in Hepatic Inflammation. Clinical and Translational Gastroenterology, 2015, 6, e95.	2.5	16
203	Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH. Metabolic Syndrome and Related Disorders, 2015, 13, 393-399.	1.3	22
204	An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes. Journal of Diabetes and Its Complications, 2015, 29, 1240-1247.	2.3	30
205	Leptin in nonalcoholic fatty liver disease: A narrative review. Metabolism: Clinical and Experimental, 2015, 64, 60-78.	3.4	170
206	Antihypertensive therapy improves insulin resistance and serum levels of interleukin-6 and â^'10 in spontaneously hypertensive rats with steatohepatitis. Molecular Medicine Reports, 2016, 14, 5385-5394.	2.4	9
207	The Immune Landscape in Nonalcoholic Steatohepatitis. Immune Network, 2016, 16, 147.	3.6	49
208	Infiltrating monocytes in liver injury and repair. Clinical and Translational Immunology, 2016, 5, e113.	3.8	75
209	C-X-C motif chemokine 10 in non-alcoholic steatohepatitis: role as a pro-inflammatory factor and clinical implication. Expert Reviews in Molecular Medicine, 2016, 18, e16.	3.9	28
210	Protective effects of glycyrrhizic acid from edible botanical glycyrrhiza glabra against non-alcoholic steatohepatitis in mice. Food and Function, 2016, 7, 3716-3723.	4.6	37
211	Promising therapies for treatment of nonalcoholic steatohepatitis. Expert Opinion on Emerging Drugs, 2016, 21, 343-357.	2.4	28
212	Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. The Lancet Gastroenterology and Hepatology, 2016, 1, 56-67.	8.1	152
213	Association of recently described adipokines with liver histology in biopsyâ€proven nonâ€alcoholic fatty liver disease: a systematic review. Obesity Reviews, 2016, 17, 68-80.	6.5	50
214	Suppression of IGF binding proteinâ€3 by palmitate promotes hepatic inflammatory responses. FASEB Journal, 2016, 30, 4071-4082.	0.5	23
215	Coral calcium hydride prevents hepatic steatosis in high fat diet-induced obese rats: A potent mitochondrial nutrient and phase II enzyme inducer. Biochemical Pharmacology, 2016, 103, 85-97.	4.4	27
216	Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies. Nature Reviews Drug Discovery, 2016, 15, 249-274.	46.4	365
217	Hepatic Transmembrane 6 Superfamily Member 2 Regulates Cholesterol Metabolism in Mice. Gastroenterology, 2016, 150, 1208-1218.	1.3	78
218	The P72R Polymorphism of p53 Predisposes to Obesity and Metabolic Dysfunction. Cell Reports, 2016, 14, 2413-2425.	6.4	95

#	Article	IF	Citations
219	Dietary Broccoli Lessens Development of Fatty Liver and Liver Cancer in Mice Given Diethylnitrosamine and Fed a Western or Control Diet. Journal of Nutrition, 2016, 146, 542-550.	2.9	52
220	Emerging Therapies for Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease, 2016, 20, 365-385.	2.1	8
221	The role of macrophages in obesity-driven chronic liver disease. Journal of Leukocyte Biology, 2016, 99, 693-698.	3.3	34
222	Kinetics of plasma procalcitonin, soluble CD14, CCL2 and IL-10 after a sublethal infusion of lipopolysaccharide in horses. Veterinary Immunology and Immunopathology, 2017, 184, 29-35.	1.2	27
223	Influence of hyperglycemia on liver inflammatory conditions in the early phase of non-alcoholic fatty liver disease in mice. Journal of Pharmacy and Pharmacology, 2017, 69, 698-705.	2.4	14
224	Classifying oxidative stress by F2-isoprostane levels across human diseases: A meta-analysis. Redox Biology, 2017, 12, 582-599.	9.0	134
225	Long-term obestatin treatment of mice type 2 diabetes increases insulin sensitivity and improves liver function. Endocrine, 2017, 56, 538-550.	2.3	16
226	Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. Journal of Hepatology, 2017, 67, 801-808.	3.7	70
227	Association of plasma dipeptidyl peptidase-4 activity with non-alcoholic fatty liver disease in nondiabetic Chinese population. Metabolism: Clinical and Experimental, 2017, 73, 125-134.	3.4	23
228	HCV-induced regulatory alterations of IL-1Î², IL-6, TNF-Î±, and IFN-Ï' operative, leading liver en-route to non-alcoholic steatohepatitis. Inflammation Research, 2017, 66, 477-486.	4.0	14
229	CD44 is a key player in non-alcoholic steatohepatitis. Journal of Hepatology, 2017, 67, 328-338.	3.7	96
230	Role of FXR in Liver Inflammation During Nonalcoholic Steatohepatitis. Current Pharmacology Reports, 2017, 3, 92-100.	3.0	69
231	Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2017, 11, S209-S216.	3.6	136
232	Human immunodeficiency virusâ€"infected and uninfected adults with nonâ€"genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection. Hepatology, 2017, 65, 853-863.	7.3	25
233	Do Genetic Markers of Inflammation Modify the Relationship between Periodontitis and Nonalcoholic Fatty Liver Disease? Findings from the SHIP Study. Journal of Dental Research, 2017, 96, 1392-1399.	5.2	24
234	Model for endâ€stage liver disease Na Score predicts incident major cardiovascular events in patients with nonalcoholic fatty liver disease. Hepatology Communications, 2017, 1, 429-438.	4.3	9
235	Angiogenic factor with G patch and FHA domains 1 (Aggf1) promotes hepatic steatosis in mice. Biochemical and Biophysical Research Communications, 2017, 482, 134-140.	2.1	2
236	Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology, 2017, 65, 65-77.	7.3	134

#	Article	IF	Citations
237	CD98 siRNA-loaded nanoparticles decrease hepatic steatosis in mice. Digestive and Liver Disease, 2017, 49, 188-196.	0.9	16
238	Hepatic recruitment of CD11b+Ly6C+ inflammatory monocytes promotes hepatic ischemia/reperfusion injury. International Journal of Molecular Medicine, 2018, 41, 935-945.	4.0	26
239	Cytokines in the Liver. , 2017, , 75-96.		2
240	Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. Nutrients, 2017, 9, 387.	4.1	362
241	Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis. Nutrients, 2017, 9, 1006.	4.1	28
242	Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Mice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis. Nutrients, 2017, 9, 1220.	4.1	120
243	Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review. Sao Paulo Medical Journal, 2017, 135, 277-295.	0.9	35
244	Î±-Mangostin ameliorates hepatic steatosis and insulin resistance by inhibition C-C chemokine receptor 2. PLoS ONE, 2017, 12, e0179204.	2.5	20
245	Transcriptomics, metabolomics and histology indicate that high-carbohydrate diet negatively affects the liver health of blunt snout bream (Megalobrama amblycephala). BMC Genomics, 2017, 18, 856.	2.8	77
246	Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2017, 23, 3407.	3.3	74
247	Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory Response in Hepatocytes and Macrophages. Cell Reports, 2018, 23, 1099-1111.	6.4	406
248	Exposure to environmental level phenanthrene induces a NASH-like phenotype in new born rat. Environmental Pollution, 2018, 239, 261-271.	7.5	17
249	Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis. Journal of Biological Chemistry, 2018, 293, 8656-8671.	3.4	35
250	Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis. Expert Opinion on Investigational Drugs, 2018, 27, 301-311.	4.1	95
251	Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. Annual Review of Pathology: Mechanisms of Disease, 2018, 13, 321-350.	22.4	387
252	Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis. Biochemical and Biophysical Research Communications, 2018, 497, 207-213.	2.1	5
253	ValoraciÃ³n de la enfermedad por hÃgado graso no alcohÃ³lico desde el laboratorio clÃnico. Revista Del Laboratorio ClÃnico, 2018, 11, 163-173.	0.1	1
254	Prostaglandin I ₂ suppresses the development of dietâ€induced nonalcoholic steatohepatitis in mice. FASEB Journal, 2018, 32, 2354-2365.	0.5	8

#	Article	IF	Citations
255	TRUSS Exacerbates NAFLD Development by Promoting IÎºBÎ± Degradation in Mice. Hepatology, 2018, 68, 1769-1785.	7.3	10
256	Liver volume and hepatic adiposity in childhood: relations to body growth and visceral fat. International Journal of Obesity, 2018, 42, 65-71.	3.4	8
257	Effects and mechanisms of caffeine to improve immunological and metabolic abnormalities in diet-induced obese rats. American Journal of Physiology - Endocrinology and Metabolism, 2018, 314, E433-E447.	3.5	20
258	Non-alcoholic Fatty Liver Disease: What We Learn from Omics Studies. , 0, , .		0
259	Reactive hyperemia index can screen endothelial dysfunction in obese subjects with non-alcoholic fatty liver disease. Vascular Failure, 2018, 2, 39-44.	0.2	0
260	Inhibition of CCL19 benefits nonâ€'alcoholic fatty liver disease by inhibiting TLR4/NFâ€'ÎºBâ€'p65 signaling. Molecular Medicine Reports, 2018, 18, 4635-4642.	2.4	9
261	Serum Interleukinâ€8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Hepatology Communications, 2018, 2, 1344-1355.	4.3	58
262	Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis. Archives of Medical Science, 2018, 14, 1233-1244.	0.9	39
263	GlutathioneS-transferase P deficiency induces glucose intolerance via JNK-dependent enhancement of hepatic gluconeogenesis. American Journal of Physiology - Endocrinology and Metabolism, 2018, 315, E1005-E1018.	3.5	14
264	Are Vaspin and Omentin-1 Related to Insulin Resistance, Blood Pressure and Inflammation in NAFLD Patients?. Journal of Medical Biochemistry, 2018, 37, 470-475.	1.7	18
265	CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease. American Journal of Physiology - Renal Physiology, 2018, 314, G483-G493.	3.4	46
266	Lactoferrin attenuates high-fat diet-induced hepatic steatosis and lipid metabolic dysfunctions by suppressing hepatic lipogenesis and down-regulating inflammation in C57BL/6J mice. Food and Function, 2018, 9, 4328-4339.	4.6	24
267	Zinc regulates vascular endothelial cell activity through zinc-sensing receptor ZnR/GPR39. American Journal of Physiology - Cell Physiology, 2018, 314, C404-C414.	4.6	64
268	Serum levels of immunoglobulins in an adult population and their relationship with nonalcoholic fatty liver disease. Journal of Digestive Diseases, 2018, 19, 498-507.	1.5	5
269	miR-122 inhibition in a human liver organoid model leads to liver inflammation, necrosis, steatofibrosis and dysregulated insulin signaling. PLoS ONE, 2018, 13, e0200847.	2.5	44
270	Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. Cardiovascular Diabetology, 2018, 17, 28.	6.8	43
271	Dietary fat stimulates development of NAFLD more potently than dietary fructose in Spragueâ€"Dawley rats. Diabetology and Metabolic Syndrome, 2018, 10, 4.	2.7	58
272	Catalase and nonalcoholic fatty liver disease. Pflugers Archiv European Journal of Physiology, 2018, 470, 1721-1737.	2.8	48

#	Article	IF	Citations
273	Molecular Basis of Liver Disease. , 2018, , 417-456.		0
274	Cranberry Attenuates Progression of Non-alcoholic Fatty Liver Disease Induced by High-Fat Diet in Mice. Biological and Pharmaceutical Bulletin, 2019, 42, 1295-1302.	1.4	11
275	Assay validation and clinical performance of chronic inflammatory and chemokine biomarkers of NASH fibrosis. PLoS ONE, 2019, 14, e0217263.	2.5	15
276	Nonalcoholic fatty liver disease and alcoholic liver disease: metabolic diseases with systemic manifestations. Translational Gastroenterology and Hepatology, 2019, 4, 65-65.	3.0	11
277	Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Cells, 2019, 8, 1259.	4.1	67
278	Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date. Pharmaceutical Medicine, 2019, 33, 451-463.	1.9	12
279	Sodium hydrosulphide restores tumour necrosis factorâ€Î±â€induced mitochondrial dysfunction and metabolic dysregulation in HLâ€1 cells. Journal of Cellular and Molecular Medicine, 2019, 23, 7641-7650.	3.6	9
280	Knockout of neutrophil elastase protects against western diet induced nonalcoholic steatohepatitis in mice by regulating hepatic ceramides metabolism. Biochemical and Biophysical Research Communications, 2019, 518, 691-697.	2.1	30
281	Gut Dysfunction and Non-alcoholic Fatty Liver Disease. Frontiers in Endocrinology, 2019, 10, 611.	3.5	69
282	Sphingosine 1-Phosphate Receptor Blockade Affects Pro-Inflammatory Bone Marrow-Derived Macrophages and Relieves Mouse Fatty Liver Injury. International Journal of Molecular Sciences, 2019, 20, 4695.	4.1	11
283	Interplay between early-life malnutrition, epigenetic modulation of the immune function and liver diseases. Nutrition Research Reviews, 2019, 32, 128-145.	4.1	40
284	Influence of total polar compounds on lipid metabolism, oxidative stress and cytotoxicity in HepG2 cells. Lipids in Health and Disease, 2019, 18, 37.	3.0	18
285	Hepatic Fat Content and Liver Enzymes Are Associated with Circulating Free and Protein-Bound Advanced Glycation End Products, Which Are Associated with Low-Grade Inflammation: The CODAM Study. Journal of Diabetes Research, 2019, 2019, 1-10.	2.3	10
286	The incretin enhancer, sitagliptin, exacerbates expression of hepatic inflammatory markers in rats fed a high-cholesterol diet. Inflammation Research, 2019, 68, 581-595.	4.0	6
287	Liver Fat Is Associated With Markers of Inflammation and Oxidative Stress in Analysis of Data From the Framingham Heart Study. Clinical Gastroenterology and Hepatology, 2019, 17, 1157-1164.e4.	4.4	62
288	Noninvasive diagnostic criteria for nonalcoholic steatohepatitis based on gene expression levels in peripheral blood mononuclear cells. Journal of Gastroenterology, 2019, 54, 730-741.	5.1	11
289	Liver macrophages regulate systemic metabolism through non-inflammatory factors. Nature Metabolism, 2019, 1, 445-459.	11.9	72
290	Non-alcoholic fatty liver disease presence and severity are associated with aortic stiffness beyond abdominal obesity: The ELSA-Brasil. Atherosclerosis, 2019, 284, 59-65.	0.8	15

#	Article	IF	Citations
291	Myeloid cell deletion of Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) induces non-alcoholic steatohepatitis. PLoS ONE, 2019, 14, e0225332.	2.5	6
292	Macrophage Function in the Pathogenesis of Non-alcoholic Fatty Liver Disease: The Mac Attack. Frontiers in Immunology, 2019, 10, 2893.	4.8	58
293	Adipocytokines in Steatotic Liver Surgery/Transplantation. Transplantation, 2019, 103, 71-77.	1.0	4
294	The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 258-267.	1.5	25
295	A comparative analysis of hepatic pathological phenotypes in C57BL/6J and C57BL/6N mouse strains in non-alcoholic steatohepatitis models. Scientific Reports, 2019, 9, 204.	3.3	33
296	Chronic intake of moderate fat-enriched diet induces fatty liver and low-grade inflammation without obesity in rabbits. Chemico-Biological Interactions, 2019, 300, 56-62.	4.0	9
297	Effects of palmitate and astaxanthin on cell viability and proinflammatory characteristics of mesenchymal stem cells. International Immunopharmacology, 2019, 68, 164-170.	3.8	22
298	A Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. Hepatology, 2019, 69, 1520-1534.	7.3	36
299	Perilipinâ€2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extraâ€hepatocyte actions. Journal of Physiology, 2019, 597, 1565-1584.	2.9	56
300	Wuzhi capsule (Schisandra Sphenanthera extract) attenuates liver steatosis and inflammation during non-alcoholic fatty liver disease development. Biomedicine and Pharmacotherapy, 2019, 110, 285-293.	5.6	29
301	Unravelling fatty liver haemorrhagic syndrome: 1. Oestrogen and inflammation. Avian Pathology, 2020, 49, 87-98.	2.0	14
302	Molecular and ultrastructure study of endoplasmic reticulum stress in hepatic steatosis: role of hepatocyte nuclear factor 4Î± and inflammatory mediators. Histochemistry and Cell Biology, 2020, 153, 49-62.	1.7	11
303	The intestinal microbiota fuelling metabolic inflammation. Nature Reviews Immunology, 2020, 20, 40-54.	22.7	573
304	Polarized light therapy: Shining a light on the mechanism underlying its immunomodulatory effects. Journal of Biophotonics, 2020, 13, e201960177.	2.3	12
305	Nonalcoholic Fatty Liver Disease. Hypertension, 2020, 75, 275-284.	2.7	121
306	Lycopene induces insulin signaling and alleviates fibrosis in experimental model of non-alcoholic fatty liver disease in rats. PharmaNutrition, 2020, 14, 100225.	1.7	5
307	Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study. European Journal of Internal Medicine, 2020, 82, 68-75.	2.2	22
308	ASC, IL-18 and Galectin-3 as Biomarkers of Non-Alcoholic Steatohepatitis: A Proof of Concept Study. International Journal of Molecular Sciences, 2020, 21, 8580.	4.1	18

#	Article	IF	Citations
309	Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome. Science Translational Medicine, 2020, 12, .	12.4	122
310	The role of neutrophils in innate immunity-driven nonalcoholic steatohepatitis: lessons learned and future promise. Hepatology International, 2020, 14, 652-666.	4.2	34
311	Breath Biopsy Assessment of Liver Disease Using an Exogenous Volatile Organic Compoundâ€"Toward Improved Detection of Liver Impairment. Clinical and Translational Gastroenterology, 2020, 11, e00239.	2.5	34
312	Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality. PLoS ONE, 2020, 15, e0238824.	2.5	4
313	Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments. Frontiers in Pharmacology, 2020, 11, 603926.	3.5	115
314	FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Frontiers in Endocrinology, 2020, 11, 601290.	3.5	111
315	CML/RAGE Signal Bridges a Common Pathogenesis Between Atherosclerosis and Non-alcoholic Fatty Liver. Frontiers in Medicine, 2020, 7, 583943.	2.6	8
316	The Molecular and Mechanistic Insights Based on Gutâ€"Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement. International Journal of Molecular Sciences, 2020, 21, 3066.	4.1	68
317	Immune modulating effects of additional supplementation of estradiol combined with testosterone in murine testosterone-deficient NAFLD model. American Journal of Physiology - Renal Physiology, 2020, 318, G989-G999.	3.4	18
318	Pharmacological inhibition of P2RX7 ameliorates liver injury by reducing inflammation and fibrosis. PLoS ONE, 2020, 15, e0234038.	2.5	26
319	Dyslipidemic Diet Induces Mobilization of Peripheral Neutrophils and Monocytes That Exacerbate Hemorrhagic Brain Injury and Neuroinflammation. Frontiers in Cellular Neuroscience, 2020, 14, 154.	3.7	8
320	Effect of Ginger Powder Supplementation in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial . Clinical and Experimental Gastroenterology, 2020, Volume 13, 35-45.	2.3	28
321	Hepatoprotective Effect of Cranberry Nutraceutical Extract in Non-alcoholic Fatty Liver Model in Rats: Impact on Insulin Resistance and Nrf-2 Expression. Frontiers in Pharmacology, 2020, 11, 218.	3.5	33
322	Obeticholic acid for the treatment of nonalcoholic steatohepatitis. Expert Review of Gastroenterology and Hepatology, 2020, 14, 311-321.	3.0	30
323	Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis. Journal of Hepatology, 2021, 74, 511-521.	3.7	23
324	The pivotal role of heme Oxygenase-1 in reversing the pathophysiology and systemic complications of NAFLD. Archives of Biochemistry and Biophysics, 2021, 697, 108679.	3.0	12
325	Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets. Translational Research, 2021, 231, 24-38.	5.0	21
326	Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease. Thrombosis Research, 2021, 198, 139-150.	1.7	27

#	Article	IF	Citations
327	Inhibition of hyaluronan synthesis by 4-methylumbelliferone ameliorates non-alcoholic steatohepatitis in choline-deficient l-amino acid-defined diet-induced murine model. Archives of Pharmacal Research, 2021, 44, 230-240.	6.3	8
328	The Association Between Nonalcoholic Fatty Liver Disease and Risk of Cardiovascular Disease, Stroke, and Extrahepatic Cancers. Journal of Clinical and Experimental Hepatology, 2021, 11, 45-81.	0.9	12
329	Research Progress of Intrahepatic Macrophages in Metabolism-Related Fatty Liver Disease. Advances in Clinical Medicine, 2021, 11, 1608-1614.	0.0	0
330	Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease. Frontiers in Immunology, 2020, 11, 634409.	4.8	18
331	Cognitive Dysfunction in Non-Alcoholic Fatty Liver Diseaseâ€"Current Knowledge, Mechanisms and Perspectives. Journal of Clinical Medicine, 2021, 10, 673.	2.4	51
332	Group 3 Innate Lymphoid Cells Protect Steatohepatitis From High-Fat Diet Induced Toxicity. Frontiers in Immunology, 2021, 12, 648754.	4.8	25
333	Dicarbonyl stress, protein glycation and the unfolded protein response. Glycoconjugate Journal, 2021, 38, 331-340.	2.7	32
334	Role of 2â€'series prostaglandins in the pathogenesis of type 2 diabetes mellitus and nonâ€'alcoholic fatty liver disease (Review). International Journal of Molecular Medicine, 2021, 47, .	4.0	22
335	Tissue-specific role and associated downstream signaling pathways of adiponectin. Cell and Bioscience, 2021, 11, 77.	4.8	26
336	Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management. Diagnostics, 2021, 11, 689.	2.6	20
337	NAFLD and Liver Fibrosis Are Not Associated With Reduced Femoral Bone Mineral Density in the General US Population. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2856-e2865.	3.6	26
338	Chronic systemic exposure to IL6 leads to deregulation of glycolysis and fat accumulation in the zebrafish liver. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2021, 1866, 158905.	2.4	10
339	Maternal obesity accelerated nonâ€'alcoholic fatty liver disease in offspring mice by reducing autophagy. Experimental and Therapeutic Medicine, 2021, 22, 716.	1.8	5
340	Pro-Inflammatory Interleukin-18 is Associated with Hepatic Steatosis and Elevated Liver Enzymes in People with HIV Monoinfection. AIDS Research and Human Retroviruses, 2021, 37, 385-390.	1.1	7
341	Regulation and functional roles of chemokines in liver diseases. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 630-647.	17.8	46
342	UCP1 governs liver extracellular succinate and inflammatory pathogenesis. Nature Metabolism, 2021, 3, 604-617.	11.9	82
343	Role of Indole-3-Acetic Acid in NAFLD Amelioration After Sleeve Gastrectomy. Obesity Surgery, 2021, 31, 3040-3052.	2.1	15
344	Circulating tumor necrosis factorâ€Î± levels in nonâ€alcoholic fatty liver disease: A systematic review and a metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 3002-3014.	2.8	30

#	Article	IF	Citations
345	Reversal of Insulin Resistance in Overweight and Obese Subjects by trans-Resveratrol and Hesperetin Combinationâ€"Link to Dysglycemia, Blood Pressure, Dyslipidemia, and Low-Grade Inflammation. Nutrients, 2021, 13, 2374.	4.1	37
346	Immunonano-Lipocarrier-Mediated Liver Sinusoidal Endothelial Cell-Specific RUNX1 Inhibition Impedes Immune Cell Infiltration and Hepatic Inflammation in Murine Model of NASH. International Journal of Molecular Sciences, 2021, 22, 8489.	4.1	8
347	Brain-gut-liver interactions across the spectrum of insulin resistance in metabolic fatty liver disease. World Journal of Gastroenterology, 2021, 27, 4999-5018.	3.3	8
348	Crosstalk Between Plasma Cytokines, Inflammation, and Liver Damage as a New Strategy to Monitoring NAFLD Progression. Frontiers in Immunology, 2021, 12, 708959.	4.8	37
349	The Impact of NAFLD on Hospitalization Outcomes in Patients With Inflammatory Bowel Diseases: Nationwide Analysis. Inflammatory Bowel Diseases, 2022, 28, 878-887.	1.9	9
350	Multidimensional Biomarker Analysis Including Mitochondrial Stress Indicators for Nonalcoholic Fatty Liver Disease. Gut and Liver, 2022, 16, 171-189.	2.9	2
351	Clinical perspectives, assessment, and mechanisms of metabolic-associated fatty liver disease in patients with COVID-19. World Journal of Gastroenterology, 2021, 27, 5502-5519.	3.3	0
352	Mediating Roles of hsCRP, TNF-Î± and Adiponectin on the Associations between Body Fat and Fatty Liver Disease among Overweight and Obese Adults. Biology, 2021, 10, 895.	2.8	2
353	Conditioned medium from stem cells derived from human exfoliated deciduous teeth ameliorates NASH via the Gut-Liver axis. Scientific Reports, 2021, 11, 18778.	3.3	8
354	Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Diabetes and Metabolism Journal, 2021, 45, 698-707.	4.7	10
355	Association of xenobiotic-metabolizing enzymes (GSTM1 and GSTT 1), and pro-inflammatory cytokines (TNF-Î± and IL-6) genetic polymorphisms with non-alcoholic fatty liver disease. Molecular Biology Reports, 2021, 48, 1225-1231.	2.3	7
356	Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease. Immunological Medicine, 2021, 44, 175-186.	2.6	5
358	Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity. Obesity, 2016, 24, 2544-2552.	3.0	23
359	Nonalcoholic Steatohepatitis, Animal Models, and Biomarkers: What Is New?. Methods in Molecular Biology, 2010, 593, 109-136.	0.9	21
360	Non-Alcoholic Fatty Liver Disease. Advances in Experimental Medicine and Biology, 2017, 960, 443-467.	1.6	183
361	Hemolysis transforms liver macrophages into antiinflammatory erythrophagocytes. Journal of Clinical Investigation, 2020, 130, 5576-5590.	8.2	36
362	Relationship between non-alcoholic fatty liver disease and coronary heart disease. World Journal of Clinical Cases, 2020, 8, 4688-4699.	0.8	21
363	Loss of hepatocyte cell division leads to liver inflammation and fibrosis. PLoS Genetics, 2020, 16, e1009084.	3.5	29

#	Article	IF	Citations
364	Hepatic Expression Patterns of Inflammatory and Immune Response Genes Associated with Obesity and NASH in Morbidly Obese Patients. PLoS ONE, 2010, 5, e13577.	2.5	201
365	Non-Alcoholic Fatty Liver Disease Is Closely Associated with Sub-Clinical Inflammation: A Case-Control Study on Asian Indians in North India. PLoS ONE, 2013, 8, e49286.	2.5	59
366	Oral Probiotic Microcapsule Formulation Ameliorates Non-Alcoholic Fatty Liver Disease in Bio F1B Golden Syrian Hamsters. PLoS ONE, 2013, 8, e58394.	2.5	38
367	Ursolic Acid Increases Glucose Uptake through the PI3K Signaling Pathway in Adipocytes. PLoS ONE, 2014, 9, e110711.	2.5	31
368	Macrophage Stimulating Protein Enhances Hepatic Inflammation in a NASH Model. PLoS ONE, 2016, 11, e0163843.	2.5	13
370	Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD. Current Pharmaceutical Design, 2013, 19, 5280-5296.	1.9	7
372	Apoptosis and diagnosis of nonalcoholic steatohepatitis. The Korean Journal of Hepatology, 2011, 17, 247.	1.5	1
373	Blood F2-isoprostanes are significantly associated with abnormalities of lipid status in rats with steatosis. World Journal of Gastroenterology, 2008, 14, 4677.	3.3	11
374	The blind men 'see' the elephant-the many faces of fatty liver disease. World Journal of Gastroenterology, 2008, 14, 831.	3.3	40
375	Proteomic and genomic studies of non-alcoholic fatty liver disease - clues in the pathogenesis. World Journal of Gastroenterology, 2014, 20, 8325.	3.3	33
376	Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future. World Journal of Gastroenterology, 2014, 20, 10851.	3.3	93
377	Nonalcoholic fatty liver disease: A comprehensive review of a growing epidemic. World Journal of Gastroenterology, 2014, 20, 12082.	3.3	155
378	Chemokine ligand 2 and paraoxonase-1 in non-alcoholic fatty liver disease: The search for alternative causative factors. World Journal of Gastroenterology, 2015, 21, 2875.	3.3	8
379	Sex disparity in viral load, inflammation and liver damage in transgenic mice carrying full hepatitis B virus genome with the W4P mutation in the preS1 region. World Journal of Gastroenterology, 2018, 24, 1084-1092.	3.3	4
380	Immunoregulation by lipids during the development of non-alcoholic steatohepatitis. Hepatobiliary Surgery and Nutrition, 2015, 4, 11-23.	1.5	21
381	Carotenoids and non-alcoholic fatty liver disease. Hepatobiliary Surgery and Nutrition, 2015, 4, 161-71.	1.5	36
382	Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver. Advanced Biomedical Research, 2016, 5, 28.	0.5	49
383	Obesity phenotypes and resorption percentage after breast autologous fat grafting: Rule of low-grade inflammation. Advanced Biomedical Research, 2016, 5, 134.	0.5	3

#	Article	IF	Citations
384	Prevalence of asymptomatic nonalcoholic fatty liver disease in nondiabetic participants: a study from south india. The Egyptian Journal of Internal Medicine, 2019, 31, 92-98.	0.9	4
385	Erythrocyte membrane fatty acid profile & serum cytokine levels in patients with non-alcoholic fatty liver disease. Indian Journal of Medical Research, 2018, 147, 352.	1.0	8
386	Prolonged high-fat-diet feeding promotes non-alcoholic fatty liver disease and alters gut microbiota in mice. World Journal of Hepatology, 2019, 11, 619-637.	2.0	98
387	ÂVaspin, resistin, retinol-binding protein-4, interleukin-1Î± and interleukin-6 in patients with nonalcoholic fatty liver disease. Annals of Hepatology, 2016, 15, 705-14.	1.5	24
388	Effects of Green Coffee Bean Extract Supplementation on Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Clinical Trial. Hepatitis Monthly, 2017, 17, .	0.2	39
389	Biomarkers of Disease Severity in Nonalcoholic Fatty Liver Disease. The Korean Journal of Obesity, 2013, 22, 83.	0.2	1
390	Sparcl1 promotes nonalcoholic steatohepatitis progression in mice through upregulation of CCL2. Journal of Clinical Investigation, 2021, 131, .	8.2	38
392	C C chemokine ligand 3 deficiency ameliorates diet-induced steatohepatitis by regulating liver macrophage recruitment and M1/M2 status in mice. Metabolism: Clinical and Experimental, 2021, 125, 154914.	3.4	33
393	Splanchnic-Brain Crosstalk Mediated By Chemokines In Portal Hypertensive Rats. Internet Journal of Gastroenterology, 2009, 7, .	0.1	2
395	Non alcoholic fatty liver disease and its relationship with hsCRP in type 2 diabetes mellitus. International Journal of Research in Medical Sciences, 2014, 2, 1586.	0.1	0
396	Role of adipokines in the pathogenesis of nonalcoholic fatty liver disease. The Journal of Clinical and Scientific Research, 2015, 4, 31.	0.1	1
397	Diabetes and Liver Disease. , 2015, , 1-25.		0
398	Serum Adipokines in Patients with Non-alcoholic Fatty Liver Disease - Is there a Role for Predicting the Severity of Liver Disease?. Internal Medicine: Open Access, 2015, 05, .	0.0	0
399	Non-alcoholic Fatty Liver Disease in Obesity. , 2016, , 159-179.		0
400	Diabetes and Liver Disease. , 2017, , 705-729.		0
401	Diabetes and Liver Disease. , 2017, , 1-26.		0
403	Red blood cell count has an independent contribution to the prediction of ultrasonography-diagnosed fatty liver disease. PLoS ONE, 2017, 12, e0172027.	2.5	7
404	Pathogenetic substantiation of approaches
to the treatment of non-alcoholic fatty liver disease.. Klinicheskaia Meditsina, 2018, 95, 1077-1085.	0.1	0

#	Article	IF	Citations
406	SPECIFIC FEATURES OF METABOLIC DISORDERS IN MALES AND FEMALES WITH NON-ALCOHOLIC FATTY LIVER DISEASE. Juvenis Scientia, 2020, 6, 18-32.	0.2	0
407	Effects of Oxidant-Antioxidant and Vitamin D Levels on Clinical and Laboratory Data in Children With Fatty Liver Disease. Cureus, 2020, 12, e11849.	0.5	1
408	Are Vaspin and Omentin-1 Related to Insulin Resistance, Blood Pressure and Inflammation in NAFLD Patients?. Journal of Medical Biochemistry, 2018, .	1.7	0
409	Effect of Vitamin D Supplementation on C-reactive Protein in Patients with Nonalcoholic Fatty Liver. International Journal of Preventive Medicine, 2014, 5, 969-75.	0.4	36
410	Effect of pioglitazone, quercetin and hydroxy citric acid on extracellular matrix components in experimentally induced non-alcoholic steatohepatitis. Iranian Journal of Basic Medical Sciences, 2015, 18, 832-6.	1.0	9
411	The Role of Elastography in Non-Alcoholic Fatty Liver Disease. Current Health Sciences Journal, 2020, 46, 255-269.	0.2	0
412	The Neglected Role of Bile Duct Epithelial Cells in NASH. Seminars in Liver Disease, 2022, 42, 034-047.	3.6	8
413	Clerodendrum trichotomum extract improves metabolic derangements in high fructose diet-fed rats. Animal Cells and Systems, 2021, 25, 396-404.	2.2	6
414	Impact of Helicobacter pylori-Related Metabolic Syndrome Parameters on Arterial Hypertension. Microorganisms, 2021, 9, 2351.	3.6	21
415	Sitagliptin Is More Effective Than Gliclazide in Preventing ÂPro-Fibrotic and Pro-Inflammatory Changes in a Rodent Model of Diet-Induced Non-Alcoholic Fatty Liver Disease. Molecules, 2022, 27, 727.	3.8	7
416	A systematic review and metaâ€analysis of preclinical and clinical studies on the efficacy of ginger for the treatment of fatty liver disease. Phytotherapy Research, 2022, 36, 1182-1193.	5.8	12
417	Endothelial group IVA phospholipase A2 promotes hepatic fibrosis with sinusoidal capillarization in the early stage of non-alcoholic steatohepatitis in mice. Life Sciences, 2022, 294, 120355.	4.3	3
418	Is it possible to treat nonalcoholic liver disease using a flavanol-based nutraceutical approach? Basic and clinical data. Journal of Basic and Clinical Physiology and Pharmacology, 2022, 33, 703-714.	1.3	5
419	The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression. Nature Communications, 2021, 12, 7213.	12.8	51
420	Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Biomedicines, 2022, 10, 83.	3.2	71
421	<scp>l</scp>-Methionine supplementation attenuates high-fat fructose diet-induced non-alcoholic steatohepatitis by modulating lipid metabolism, fibrosis, and inflammation in rats. Food and Function, 2022, 13, 4941-4953.	4.6	14
422	Emerging Glycation-Based Therapeuticsâ€"Glyoxalase 1 Inducers and Glyoxalase 1 Inhibitors. International Journal of Molecular Sciences, 2022, 23, 2453.	4.1	18
423	Semi-automated approach for generation of biological networks on drug-induced cholestasis, steatosis, hepatitis, and cirrhosis. Toxicological Research, 2022, 38, 393-407.	2.1	3

#	Article	IF	Citations
424	Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis. Archives of Pharmacal Research, 2022, , 1.	6.3	2
425	Evaluation of C-reactive protein levels in the differentiation of non-alcoholic steatohepatitis and simple liver steatosis. Akdeniz Medical Journal, 0, , 202-207.	0.1	0
426	The promising role of CCL2 as a noninvasive marker for nonalcoholic steatohepatitis diagnosis in Egyptian populations. European Journal of Gastroenterology and Hepatology, 2021, 33, e954-e960.	1.6	3
427	Hepatic Macrophage as a Key Player in Fatty Liver Disease. Frontiers in Immunology, 2021, 12, 708978.	4.8	33
432	Hepatoprotective Effects of Ixeris chinensis on Nonalcoholic Fatty Liver Disease Induced by High-Fat Diet in Mice: An Integrated Gut Microbiota and Metabolomic Analysis. Molecules, 2022, 27, 3148.	3.8	6
433	An Update on the Chemokine System in the Development of NAFLD. Medicina (Lithuania), 2022, 58, 761.	2.0	9
434	Circulating adiponectin in patients with nonalcoholic fatty liver diseaseâ€related liver fibrosis: A systematic review and a metaâ€analysis. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 1853-1864.	2.8	5
435	Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques. Obesity Reviews, 2022, 23, .	6.5	7
436	Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis. International Journal of Molecular Sciences, 2022, 23, 6696.	4.1	24
437	Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis. Gut, 2023, 72, 392-403.	12.1	22
438	role of chemokines in liver disease. Journal of Education, Health and Sport, 2022, 12, 493-503.	0.1	0
439	Ectopic fat is associated with cardiac remodelingâ€"A comprehensive assessment of regional fat depots in type 2 diabetes using multi-parametric MRI. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	5
440	TM4SF5-Mediated Regulation of Hepatocyte Transporters during Metabolic Liver Diseases. International Journal of Molecular Sciences, 2022, 23, 8387.	4.1	2
441	Deficiency of WTAP in hepatocytes induces lipoatrophy and non-alcoholic steatohepatitis (NASH). Nature Communications, 2022, 13, .	12.8	13
442	CX3CL1/CX3CR1 interaction protects against lipotoxicity-induced nonalcoholic steatohepatitis by regulating macrophage migration and M1/M2 status. Metabolism: Clinical and Experimental, 2022, 136, 155272.	3.4	20
443	Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease. Frontiers in Pharmacology, 0, 13, .	3.5	6
444	Risk of dementia or cognitive impairment in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Frontiers in Aging Neuroscience, 0, 14, .	3.4	12
445	Association between SII and hepatic steatosis and liver fibrosis: A population-based study. Frontiers in Immunology, 0, 13, .	4.8	57

#	Article	IF	Citations
446	Coffee modulates insulin-hepatocyte nuclear factor-4Î±-Cyp7b1 pathway and reduces oxysterol-driven liver toxicity in a nonalcoholic fatty liver disease mouse model. American Journal of Physiology - Renal Physiology, 2022, 323, G488-G500.	3.4	7
447	Role of pan immune inflammatory value in the evaluation of hepatosteatosis in children and adolescents with obesity. Journal of Pediatric Endocrinology and Metabolism, 2022, 35, 1481-1486.	0.9	3
448	Wnt/betaâ€catenin signaling and its modulators in nonalcoholic fatty liver diseases. Hepatobiliary and Pancreatic Diseases International, 2023, 22, 333-345.	1.3	7
449	Serum CC-Chemokine Ligand 2 Is Associated with Visceral Adiposity but Not Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Digestive Diseases, 2023, 41, 439-446.	1.9	3
450	Tetrastigma hemsleyanum leaf extracts ameliorate NAFLD in mice with low-grade colitis via the gutâ€"liver axis. Food and Function, 2023, 14, 500-515.	4.6	8
451	Emerging pharmacological treatment options for MAFLD. Therapeutic Advances in Endocrinology and Metabolism, 2022, 13, 204201882211424.	3.2	4
452	Impaired hepatic glucose metabolism and liver-Î±-cell axis in mice with liver-specific ablation of the Hepatocyte Nuclear Factor 4Î± (Hnf4a) gene. Metabolism: Clinical and Experimental, 2023, 139, 155371.	3.4	3
453	Alpha-1-Antitrypsin Pi*MZ variant increases risk of developing hepatic events in nonalcoholic fatty liver disease patients,. Clinics and Research in Hepatology and Gastroenterology, 2023, 47, 102066.	1.5	1
454	IL-1Î² neutralization prevents diastolic dysfunction development, but lacks hepatoprotective effect in an aged mouse model of NASH. Scientific Reports, 2023, 13, .	3.3	3
455	Metabolic dysfunction-associated fatty liver disease is associated with an increase in systolic blood pressure over time: linear mixed-effects model analyses. Hypertension Research, 2023, 46, 1110-1121.	2.7	8
456	An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease. Journal of Hepatology, 2023, 78, 1048-1062.	3.7	35
457	Knockout of Purinergic P2Y6 Receptor Fails to Improve Liver Injury and Inflammation in Non-Alcoholic Steatohepatitis. International Journal of Molecular Sciences, 2023, 24, 3800.	4.1	2
458	Metabolic dysfunction-associated fatty liver disease reflects a significantly higher risk of hypertension than non-alcoholic fatty liver disease. Hypertension Research, 0, , .	2.7	1
459	Overview of Cellular and Soluble Mediators in Systemic Inflammation Associated with Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2023, 24, 2313.	4.1	7
460	Notch-mediated hepatocyte MCP-1 secretion causes liver fibrosis. JCI Insight, 2023, 8, .	5.0	7
461	Common pathogenetic pathways of Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Current Diabetes Reviews, 2023, 19, .	1.3	0
462	Risk Factors of Non-alcoholic Fatty Liver Disease in the Iranian Adult Population: A Systematic Review and Meta-analysis. Hepatitis Monthly, 2023, 23, .	0.2	6
463	Non-alcoholic fatty liver disease as an emerging risk factor and potential intervention target for atherosclerotic cardiovascular diseases. Journal of Cardiovascular Pharmacology, 2023, Publish Ahead of Print, .	1.9	2

#	Article	IF	Citations
464	Fatty liver disease in children (MAFLD/PeFLD Type 2): unique classification considerations and challenges. Therapeutic Advances in Endocrinology and Metabolism, 2023, 14, 204201882311603.	3.2	3
465	Mediterranean Diet Improves Plasma Biomarkers Related to Oxidative Stress and Inflammatory Process in Patients with Non-Alcoholic Fatty Liver Disease. Antioxidants, 2023, 12, 833.	5.1	4
466	Association of C-reactive protein with histological, elastographic, and sonographic indices of non-alcoholic fatty liver disease in individuals with severe obesity. Journal of Health, Population and Nutrition, 2023, 42, .	2.0	2
467	Association between dietary inflammation index and hypertension in participants with different degrees of liver steatosis. Annals of Medicine, 2023, 55, .	3.8	2
468	CCL2-Mediated Stromal Interactions Drive Macrophage Polarization to Increase Breast Tumorigenesis. International Journal of Molecular Sciences, 2023, 24, 7385.	4.1	3
469	FOXK1 promotes nonalcoholic fatty liver disease by mediating mTORC1-dependent inhibition of hepatic fatty acid oxidation. Cell Reports, 2023, 42, 112530.	6.4	4
470	Cellular and Molecular Mechanisms of Liver Fibrosis in Patients with NAFLD. Cancers, 2023, 15, 2871.	3.7	1
471	State of CD8+ T cells in progression from nonalcoholic steatohepatitis to hepatocellular carcinoma: From pathogenesis to immunotherapy. Biomedicine and Pharmacotherapy, 2023, 165, 115131.	5.6	1
472	The causal associations of non-alcoholic fatty liver disease with blood pressure and the mediating effects of cardiometabolic risk factors: A Mendelian randomization study. Nutrition, Metabolism and Cardiovascular Diseases, 2023, 33, 2151-2159.	2.6	0
473	Association between the platelet/high-density lipoprotein cholesterol ratio and nonalcoholic fatty liver disease: results from NHANES 2017â€“2020. Lipids in Health and Disease, 2023, 22, .	3.0	0
475	Carbon Dots as Potential Therapeutic Agents for Treating Non-Alcoholic Fatty Liver Disease and Associated Inflammatory Bone Loss. Bioconjugate Chemistry, 0, , .	3.6	0
476	A Current Approach to Non-Alcoholic Steatohepatitis in Type 2 Diabetes Mellitus Patients. Gastroenterology Insights, 2023, 14, 363-382.	1.2	0
477	A review of experimental and clinical studies on the therapeutic effects of pomegranate (<i>Punica) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Science and Nutrition, 2023, 11, 7485-7503.	3.4	1
478	Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease. Metabolites, 2023, 13, 1115.	2.9	1
479	Maternal polysorbate 80 intake promotes offspring metabolic syndrome through vertical microbial transmission in mice. Science of the Total Environment, 2024, 909, 168624.	8.0	0
480	Impact of steatotic liver disease and nonâ€alcoholic steatohepatitis on cognitive impairment in people living with <scp>HIV</scp>: A crossâ€sectional study. HIV Medicine, 2023, 24, 1233-1243.	2.2	0
481	Gender characteristics of non-alcoholic fatty liver disease course. Perm Medical Journal, 2023, 40, 11-20.	0.1	0
482	Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation. JHEP Reports, 2024, 6, 100992.	4.9	0

#	Article	IF	Citations
483	Ameliorative role of bioactive phytoconstituents targeting obesity associated NAFLD by modulation of inflammation and lipogenesis pathways: a comprehensive review. Phytochemistry Reviews, 0, , .	6.5	0
484	A combined analysis of TyG index, SII index, and SIRI index: positive association with CHD risk and coronary atherosclerosis severity in patients with NAFLD. Frontiers in Endocrinology, 0, 14, .	3.5	0
485	Prevalence of Steatotic Liver Disease Among US Adults with Rheumatoid Arthritis. Digestive Diseases and Sciences, 2024, 69, 989-1003.	2.3	0
486	Circulating Monocyte Chemoattractant Protein-1 (MCP-1) in Patients with Primary Biliary Cholangitis. International Journal of Molecular Sciences, 2024, 25, 1333.	4.1	0
487	Association between fatty liver index and controlled attenuation parameters as markers of metabolic dysfunction-associated fatty liver disease and bone mineral density: observational and two-sample Mendelian randomization studies. Osteoporosis International, 2024, 35, 679-689.	3.1	0
488	Cardiac remodelling in nonâ€alcoholic fatty liver disease in the general population. Liver International, 2024, 44, 1032-1041.	3.9	0
489	Emerging therapies for MASLD and their impact on plasma lipids. American Journal of Preventive Cardiology, 2024, 17, 100638.	3.0	0
490	Daraesoon (shoot of hardy kiwi) mitigates hyperglycemia in db/db mice by alleviating insulin resistance and inflammation. Nutrition Research and Practice, 2024, 18, 88.	1.9	0
491	Endotoxin Inflammatory Action on Cells by Dysregulated-Immunological-Barrier-Linked ROS-Apoptosis Mechanisms in Gutâ€"Liver Axis. International Journal of Molecular Sciences, 2024, 25, 2472.	4.1	0
492	Systemic immune-inflammatory biomarkers (SII, NLR, PLR and LMR) linked to non-alcoholic fatty liver disease risk. Frontiers in Immunology, 0, 15, .	4.8	0
493	Integration of transcriptomic analysis and multiple machine learning approaches identifies NAFLD progression-specific hub genes to reveal distinct genomic patterns and actionable targets. Journal of Big Data, 2024, 11, .	11.0	0